Discontinued — last reported Q1 '18
Zoetis Allowance for Doubtful Accounts Receivable (Current) increased by 11.8% to $19.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $19.00M to $19.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -3.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.00M | $17.00M | $17.00M | $25.00M | $24.00M | $21.00M | $19.00M | $20.00M | $20.00M | $18.00M | $18.00M | $20.00M | $22.00M | $19.00M | $18.00M | $19.00M | $17.00M | $18.00M | $17.00M | $19.00M |
| QoQ Change | — | -5.6% | +0.0% | +47.1% | -4.0% | -12.5% | -9.5% | +5.3% | +0.0% | -10.0% | +0.0% | +11.1% | +10.0% | -13.6% | -5.3% | +5.6% | -10.5% | +5.9% | -5.6% | +11.8% |
| YoY Change | — | — | — | — | +33.3% | +23.5% | +11.8% | -20.0% | -16.7% | -14.3% | -5.3% | +0.0% | +10.0% | +5.6% | +0.0% | -5.0% | -22.7% | -5.3% | -5.6% | +0.0% |